XML 75 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE RECOGNITION (Details) - USD ($)
$ in Thousands
4 Months Ended 12 Months Ended
Jul. 13, 2022
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements            
Total net revenue     $ 310,463 $ 331,339 $ 391,866  
Milestone fees paid   $ 220,000 220,000 220,000    
United States            
Revenue Recognition and Collaborative Arrangements            
Milestone fees paid   120,000 $ 120,000 120,000    
Net Product Sales | Geographic Concentration Risk | United States            
Revenue Recognition and Collaborative Arrangements            
Concentration Risk, Percentage     91.00%      
Net Product Sales | Geographic Concentration Risk | Rest of the world            
Revenue Recognition and Collaborative Arrangements            
Concentration Risk, Percentage     9.00%      
Royalty revenue            
Revenue Recognition and Collaborative Arrangements            
Total net revenue     $ 238,846 311,645 391,866  
GIAPREZA            
Revenue Recognition and Collaborative Arrangements            
Total net revenue     41,300      
XERAVA            
Revenue Recognition and Collaborative Arrangements            
Total net revenue     17,300      
XACDURO            
Revenue Recognition and Collaborative Arrangements            
Total net revenue     2,000      
GSK            
Revenue Recognition and Collaborative Arrangements            
Percentage of royalty payments not entitled to receive 15.00%          
Total net revenue     $ 238,846 $ 311,645 $ 391,866  
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration            
Revenue Recognition and Collaborative Arrangements            
Milestone fees paid           $ 220,000
Percentage of economic interest in any future payments made under the agreements     15.00%      
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration            
Revenue Recognition and Collaborative Arrangements            
Royalty rate for first level of annual global net sales (as a percent)     15.00%      
Annual global sales level used to determine royalty rate     $ 3,000,000      
Royalty rate for sales above first level of annual global net sales (as a percent)     5.00%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum            
Revenue Recognition and Collaborative Arrangements            
Royalty rate for combination products (as a percent)     6.50%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum            
Revenue Recognition and Collaborative Arrangements            
Royalty rate for combination products (as a percent)     10.00%      
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum            
Revenue Recognition and Collaborative Arrangements            
Royalty rate for combination products (as a percent)     6.50%      
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum            
Revenue Recognition and Collaborative Arrangements            
Royalty rate for combination products (as a percent)     10.00%      
La Jolla            
Revenue Recognition and Collaborative Arrangements            
Total net revenue   $ 19,700 $ 60,600      
La Jolla | Net Product Sales | Geographic Concentration Risk | United States            
Revenue Recognition and Collaborative Arrangements            
Concentration Risk, Percentage   96.00%        
La Jolla | Net Product Sales | Geographic Concentration Risk | Rest of the world            
Revenue Recognition and Collaborative Arrangements            
Concentration Risk, Percentage   4.00%        
La Jolla | GIAPREZA            
Revenue Recognition and Collaborative Arrangements            
Total net revenue   $ 14,200        
La Jolla | XERAVA            
Revenue Recognition and Collaborative Arrangements            
Total net revenue   $ 5,500